Novartis USFCC QA/QC Testing & Administration Facility

Novartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration Facility

slideslideslideslideslideslideslide

*
Novartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration FacilityNovartis - USFCC QA/QC Testing & Administration Facility

An atmosphere of cooperation

LocationHolly Springs, North Carolina

RecognitionISPE Facility of the YearAIA Wisconsin, Special RecognitionIIDA Wisconsin Design Award, First Place

When a devastating flu outbreak hits, Novartis will be ready. At its Holly Springs location, Novartis has the capability to produce cell-based seasonal flu vaccine, pre-pandemic vaccine, and 150 million doses of vaccine within six months of the declaration of an influenza pandemic.

Responding to health crises of such proportions requires facilities that are both highly efficient and flexible. Flad Architects equipped the new quality control, testing, and administration building with BSL-2 labs that could be quickly and easily transformed to BSL-3 spaces. The facility includes common spaces such as shared entrance, dining, conference, and training areas in order to encourage communication, camaraderie, and cohesion between the quality control and quality assurance departments. These features not only expedite vaccine production, but they create an atmosphere of cooperation in pursuit of a vital goal.

quote

Novartis is proud that our Holly Springs facility is the first of its kind in the United States, a testament to our commitment to help protect public health by providing innovative vaccines. We expect that this facility will play an important part toward ensuring a sufficient supply of flu vaccines in the event of a pandemic.

Vas Narasimhan, MDPresidentUS Vaccines

©2018 Flad ArchitectsFacebookInstagramLinkedIn